Leerink Swann Lowers Revenue Estimate, Cuts Price Target on Helicos' Stock | GenomeWeb
NEW YORK (GenomeWeb News) – Investment bank Leerink Swann has cut its 12-month price target for Helicos BioSciences’ stock to $6 from $10 and has roughly halved its revenue estimates for the firm for fiscal years 2008-2010.
 
Leerink Swann analyst John Sullivan in a research note cited “execution problems” in the second quarter for Helicos, as well as limited “commercial visibility” in the near-term for the firm’s flagship product, the HeliScope single molecule sequencer.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.